The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
Abstract
BACKGROUND: Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders. The associated long-term risks of infection remain poorly defined. METHODS: From July 2001 through December 2003, all patients who received alemtuzumab for the treatment of lymphoproliferative disorders at 1 institution underwent a retrospective evaluation to document infectious complications until death or end of follow-up in October 2004. Alemtuzumab recipients who underwent allogeneic hematopoietic stem cell transplantation were compared with a concurrent cohort who also underwent allogeneic hematopoietic stem cell transplantation but did not receive alemtuzumab. RESULTS: Twenty-seven patients were identified (21 with chronic lymphocytic leukemia and 6 with plasma cell disorders). The overall mortality was 37%, with 7 of 10 deaths being related to infection. Significant opportunistic infections occurred in 9 patients (43%) with chronic lymphocytic leukemia, including cytomegalovirus, progressive multifocal leukoencephalopathy, adenovirus, toxoplasmosis, and acanthamaebiasis. Thirty nonopportunistic infections in 22 patients (82%) were also identified. The 3 deaths related to nonopportunistic infections all involved Enterococcus species bacteremia. When compared with a concurrent chronic lymphocytic leukemia cohort that underwent allogeneic hematopoietic stem cell transplantation, alemtuzumab recipients had an incidence of cytomegalovirus reactivation of 66.7% (6 of 9 patients), compared with 37% in the non-alemtuzumab group (10 of 27 patients; P = .15), and an incidence of post-transplant opportunistic infections (excluding herpesviruses) of 44.4% (compared with 29.6% in the non-alemtuzumab group; P = .41). CONCLUSIONS: Despite the use of herpesvirus and Pneumocystis pneumonia prophylaxis, serious infectious complications occur in patients receiving alemtuzumab for lymphoproliferative disorders. Infectious complications are more varied and diverse in patients receiving alemtuzumab than has been reported in trials to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Kirk, A. D., Hale, D. A., Mannon, R. B., Kleiner, D. E., Hoffmann, S. C., Kampen, R. L., Cendales, L. K., Tadaki, D. K., Harlan, D. M., & Swanson, S. J. (2003) · Transplantation · doi:10.1097/01.tp.0000071362.99021.d9 · Cited by 436
Clinical Approach to Infection in the Compromised Host
(1995) · Springer eBooks · doi:10.1007/978-1-4615-6642-7 · Cited by 337
Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 307
CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS
Calne, R., Moffatt, S. D., Friend, P. J., Jamieson, N. V., Bradley, J. A., Hale, G., Firth, J., Bradley, J. R., Smith, K. G. C., & Waldmann, H. (1999) · Transplantation · doi:10.1097/00007890-199911270-00032 · Cited by 305
Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3257 · Cited by 255
ÖSterborg, A., Fassas, A. S., Anagnostopoulos, A., Dyer, M. J. S., Catovsky, D., & Mellstedt, H. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.450989.x · Cited by 228
Infection in the Organ Transplant Recipient
Rubin, R. H. (1994) · Clinical Approach to Infection in the Compromised Host · doi:10.1007/978-1-4615-2490-8_24 · Cited by 216
Ho, A. Y. L., Pagliuca, A., Kenyon, M., Parker, J. E., Mijovic, A., Devereux, S., & Mufti, G. J. (2004) · Blood · doi:10.1182/blood-2003-12-4207 · Cited by 203
Hale, G., Jacobs, P., Wood, L., Fibbe, W., Barge, R. M. Y., Novitzky, N., Toit, C., Abrahams, L., Thomas, V., Bunjes, D. W., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702477 · Cited by 166
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S. H., Kurzrock, R., Lerner, S. A., Kontoyiannis, D. P., & Keating, M. J. (2003) · Cancer · doi:10.1002/cncr.11551 · Cited by 127
Lundin, J., Porwit-MacDonald, A., Rossmann, E. D., Karlsson, C., Edman, P., Rezvany, M. R., Kimby, E., Österborg, A., & Mellstedt, H. (2004) · Leukemia · doi:10.1038/sj.leu.2403258 · Cited by 118
Uppenkamp, M. J., Engert, A., Diehl, V., Bunjes, D. W., Huhn, D., & Brittinger, G. (2001) · Annals of Hematology · doi:10.1007/s00277-001-0394-7 · Cited by 78
Infection in the Organ Transplant Recipient
Rubin, R. H. (2002) · Springer eBooks · doi:10.1007/0-306-47527-8_17 · Cited by 65
Rubin, R. H., Ikonen, T. S., Gummert, J. F., & Morris, R. E. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.10104.x · Cited by 61
James, L. C., Hale, G., Waldman, H., & Bloomer, A. C. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2750 · Cited by 47
Cited by
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22128 · Cited by 433
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Ljungman, P., Hakki, M., & Boeckh, M. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.011 · Cited by 423
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Clark, R. A., Watanabe, R., Teague, J. E., Schlapbach, C., Tawa, M. C., Adams, N., Dorosario, A. A., Chaney, K. S., Cutler, C. S., LeBoeuf, N. R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003008 · Cited by 367
Metadata
- Authors
- Martin, S. I., Marty, F. M., Fiumara, K., Treon, S. P., Gribben, J. G., & Baden, L. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 16-24
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2124607883
- Cited by
- 272
- References
- 19
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.